BIOVENTUS INC Reports Second Quarter Earnings Results for Fiscal Year 2023
August 20, 2023
🌥️Earnings Overview
On August 8 2023, BIOVENTUS INC ($NASDAQ:BVS) reported its earnings results for the second quarter of the fiscal year 2023 (ending June 30 2023). Despite a 2.3% decrease in total revenue from the same period of the previous year, the company’s net income improved to -3.7 million from -7.2 million in the prior year.
Price History
The company’s stock opened at $3.9 and closed at the same price, representing a 14.1% increase from its previous closing price of 3.4. This marked the second quarter in a row that BIOVENTUS INC had reported an increase in earnings. The company attributed its success to increased sales of their products, particularly in the orthopedic care and biologics divisions.
Additionally, BIOVENTUS INC has been actively investing in new technologies and expanding its global presence. This has allowed the company to better serve customers and remain competitive in the industry. Overall, BIOVENTUS INC has demonstrated strong financial performance this quarter. Investors are encouraged by the company’s financial results and outlook for the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bioventus Inc. More…
| Total Revenues | Net Income | Net Margin |
| 510.62 | -283.01 | 6.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bioventus Inc. More…
| Operations | Investing | Financing |
| 17.83 | -41.3 | 10.35 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bioventus Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 836.96 | 603.62 | 2.92 |
Key Ratios Snapshot
Some of the financial key ratios for Bioventus Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.6% | -8.4% | -58.2% |
| FCF Margin | ROE | ROA |
| 1.5% | -100.0% | -22.2% |
Analysis
At GoodWhale, we have recently conducted an analysis of BIOVENTUS INC and have come to the conclusion that it is a high-risk investment. Our Risk Rating tool has detected 3 risk warnings in the income sheet, balance sheet and cashflow statement. It is important to note that our Risk Rating tool assesses both the financial and business aspects and is a great resource for investors looking to make informed decisions. The risk warnings we have detected include issues with liquidity, profitability, and solvency. These are all important indicators of the overall health of a company and should be taken into consideration before investing. Furthermore, our Risk Rating system also provides detailed information on the financial performance of the company. This includes revenue growth, operating margin, cash flow, and more. In order to access the full report and analysis, you must become a registered user. We provide detailed insights into both the financial and business aspects of the company, making it easy to make an informed decision. With all this information at hand, you can make an educated decision on whether BIOVENTUS INC is the right investment for you. More…
Peers
The market for bioventus is highly competitive with Motus GI Holdings Inc, Lucid Diagnostics Inc, Reshape Lifesciences Inc, all vying for a share of the pie. Bioventus Inc has a strong product portfolio and is well-positioned to compete in this market.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that focuses on the development of endoscopic devices to provide gastrointestinal access and improve clinical outcomes. The company’s market cap as of 2022 is 5.93M and its ROE is -183.03%. Motus GI’s products are designed to provide superior clinical outcomes and improve patient safety by reducing procedural time, minimizing tissue trauma, and enhancing endoscopic visualization.
– Lucid Diagnostics Inc ($NASDAQ:LUCD)
Lucid Diagnostics Inc is a medical diagnostic company that develops and commercializes technology for the early detection of life-threatening diseases. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers. Lucid has a market cap of 71.74M as of 2022, a Return on Equity of -67.45%. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers.
– Reshape Lifesciences Inc ($NASDAQ:RSLS)
Reshape Lifesciences Inc is a biotechnology company that focuses on the development of therapies for the treatment of obesity and related diseases. The company has a market cap of 6.99M as of 2022 and a return on equity of -124.4%. Reshape Lifesciences Inc is headquartered in San Diego, California.
Summary
BIOVENTUS INC reported second quarter earnings of USD 137.1 million in revenue, a 2.3% decrease from the same period in the prior year. Net income improved from -7.2 million to -3.7 million. The company’s stock price rose on the news, suggesting that investors saw the improved net income as an encouraging sign.
Further, the company has been able to maintain revenue despite the pandemic-induced economic downturn. Thus overall, BIOVENTUS INC looks like a very attractive investment for those with a long-term horizon.
Related Posts
Recent Posts
